Summary & Overview
HCPCS Q2037: Influenza Vaccine (Fluvirin) IM, Age ≥3
HCPCS Level II code Q2037 denotes the intramuscular, split-virus influenza vaccine (Fluvirin) for individuals aged 3 years and older. This immunization code is nationally significant because seasonal influenza vaccination is a key public health intervention that reduces morbidity, hospitalizations, and healthcare utilization each year. Accurate coding ensures proper vaccine tracking, billing, and coverage determination across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q2037 represents clinically, where the vaccine is typically administered, and which payers commonly reimburse this product. The publication outlines benchmarks and payer coverage patterns, summarizes relevant policy contexts affecting influenza vaccine billing, and provides clinical context for patient eligibility and age indications.
This summary equips billing professionals, immunization program managers, and clinicians with the essential facts needed to identify Q2037 on claims, understand typical service settings, and anticipate payer interactions. Data not available in the input are noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code Q2037 represents an influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin). This code denotes administration of a standard-dose, inactivated split-virus influenza vaccine formulation intended for intramuscular injection in patients aged three years and older.
Service Type: Vaccine administration / Immunization
Typical Site of Service: Outpatient clinics, physician offices, retail pharmacies, community vaccination sites, and other ambulatory care settings
Clinical & Coding Specifications
Clinical Context
A 35-year-old adult presents to a primary care clinic during influenza season requesting routine immunization. The patient has no acute febrile illness, has completed screening for contraindications (such as severe egg allergy or prior severe vaccine reaction), and consents to vaccination. The clinical workflow includes patient intake and screening, documentation of informed consent and vaccine lot number/expiration, administration of the intramuscular influenza vaccine Q2037 (Fluvirin) in the deltoid muscle, observation for 15 minutes for immediate adverse reaction in patients with prior allergic history, and entry of the immunization into the medical record and state immunization registry as required. Typical billing captures the vaccine product with HCPCS level II code Q2037, and an administration CPT (see related CPT codes) or facility-specific administration reporting as required by the payor. Typical site of service is an outpatient clinic, urgent care, or community immunization clinic. Typical patient scenario: an adult aged ≥3 years receiving seasonal split-virus intramuscular influenza vaccine during a preventive care or opportunistic visit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Original reference to an unspecified general modifier (not commonly used clinically) |